Navigation Links
ACD Wins $3 Million Grant From National Cancer Institute to Develop Its CTCscope™ System for Detection and Molecular Analysis of Circulating Tumor Cells
Date:10/8/2010

HAYWARD, Calif., Oct. 8 /PRNewswire/ -- Advanced Cell Diagnostics, Inc. (ACD) was awarded a three-year, $3 million grant from National Cancer Institute (NCI) under its SBIR Phase II Bridge Award. This grant will support ACD's continuing effort to develop its proprietary CTCscope™ system capable of automatic detection and molecular characterization of circulating tumor cells (CTCs). CTCs are the rare tumor cells detached from solid tumors and circulating in cancer patients' blood.

"We are very grateful for the continued support from NCI. The previous Phase I and Phase II grants have helped ACD to develop the underlying RNAscope™ technology, which has since been translated successfully into Research Use Only products for in situ detection of RNA biomarkers in FFPE samples," commented by Dr. Yuling Luo, President & CEO of ACD.  "Given how few of these grants are given, the award is a further validation of the strength of our technology to uniquely fulfill a critical unmet clinical need in cancer management." ACD has since been featured as one of the NCI SBIR Success Stories (http://sbir.cancer.gov/success/stories/acd/acd.asp).

In this latest grant, ACD will work with a multidisciplinary team from four leading institutions to further advance CTCscope™ into an automated system and conduct clinical studies to demonstrate its clinical utility. Collaborators include Dr. Paul Goodwin of Applied Precision, Drs. Hope Rugo and John Park of University of California San Francisco, Prof. David Krag of University of Vermont, and Prof. Charles Coombes of Imperial College London.

About CTCscope™:

ACD's CTCscope™ system is based on its proprietary in situ RNA detection platform RNAscope™, which enables highly sensitive and specific detection of all types of CTCs without the need for EpCAM-based enrichment. Importantly, CTCscope™ is the only technology that detects those CTCs still alive while circulating in cancer patients' blood. These are the rare tumor cells that have the potential to metastasize to distant sites and thus are the targets of chemo- and targeted therapies. CTCscope™ identifies the molecular phenotypes of CTCs for guiding treatment decisions and allows real-time monitoring of therapy response.

About Advanced Cell Diagnostics (www.acdbio.com)

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. The company's products and services are based on its proprietary RNAscope™ technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases. These partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners' targeted therapeutics. ACD also pursues internal programs to develop proprietary diagnostic tests in cancer management.Contact: Steve Chen, Ph.D. Chief Operating Officer (510) 576-8800 ext 102 schen@acdbio.com
'/>"/>

SOURCE Advanced Cell Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. Atritech Announces Completion of a $22 Million Equity Financing
3. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
4. EntreMed Raises $20 Million to Support Clinical Development Program
5. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
6. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
7. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
8. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
9. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
10. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
11. 38.7 Million People Break Guinness World Record for Stand Up Speak Out on International Day for the Eradication of Poverty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ORANGE COUNTY, Calif. , Oct. 10, 2017  NDS received ... Mobile  — a medical-grade battery-powered display stand specifically designed for ... aims to transform technology into a clinical solution to support the ... costs. Innovative Design ... NDS ZeroWire Mobile Wireless Solution ...
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many ... event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids ... of all ages; it is a non-competitive, non-timed event, which is all about having ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
Breaking Medicine News(10 mins):